Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord mesenchymal stem cell therapy - Kangstem Biotech

Next Previous
Drug Profile

Umbilical cord mesenchymal stem cell therapy - Kangstem Biotech

Alternative Names: FURESTEM; FURESTEM-AD; FURESTEM-AD inj; FURESTEM-CD; FURESTEM-CD Inj; FURESTEM-OA Kit Inj; FURESTEM-RA; hUCB-MSCs

Latest Information Update: 04 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kangstem Holdings
  • Developer Daewoong Pharmaceutical; Kangstem Biotech
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Rheumatoid arthritis
  • Phase I/II Crohn's disease; Epidermolysis bullosa dystrophica
  • No development reported Plaque psoriasis
  • Discontinued Amyotrophic lateral sclerosis; Cancer; Diabetes mellitus; Niemann-Pick diseases; Pain; Retinal disorders

Most Recent Events

  • 31 Aug 2023 Kang Stem Biostem plans a follow-up observational trial (K0701-E) for Knee Osteoarthritis who participated in K0701 trial (NCT06013306)
  • 14 Jul 2023 Kangstem Biotech plans a phase I/II trial for Osteoarthritis (Intra-articular) (NCT05944627)
  • 06 Jul 2023 Kang Stem Biotech plans a phase I/II trial K0701 for Knee Osteoarthritis (NCT05944627)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top